WASHINGTON (Reuters) -The U.S. Senate well being panel stated on Tuesday it will vote this month on whether or not to subpoena Novo Nordisk (NYSE:) to reply questions on U.S. costs for weight reduction medication Ozempic and Wegovy, that are far larger than these in different nations.
The Senate Committee on Well being, Schooling, Labor, and Pensions, which is investigating the medication’ prices, stated in an announcement that at its June 18 assembly it is going to weigh a subpoena requiring renior Novo Nordisk Inc govt Doug Langa to testify at a July 10 listening to.
“The HELP Committee has reached out time and time again to Novo Nordisk to request their voluntary attendance at a hearing to discuss why they are charging Americans up to 10 or 15 times more for the exact same product sold in other countries,” stated Senator Bernie Sanders, who chairs the committee.
“Unfortunately, despite all of our efforts, they have repeatedly denied our requests. We look forward to their presence at a hearing on July 10th,” he stated within the assertion.
In April, Sanders despatched a letter to Langa looking for extra info on U.S. costs for the 2 medication.
Novo responded with a Could letter blaming the U.S. well being system for the excessive costs. It stated it retains about 60% of the listing worth for the medication after rebates and costs paid to middlemen.
A 2 milligram bundle of Ozempic carries an inventory worth of $935.77 within the U.S., whereas Wegovy has an inventory worth of $1,349.02 per bundle, in line with the drugmaker’s web site.
